Home
- BeiGene Facts
- Founded 2010
- Listings NASDAQ: BGNE HKEX: 06160
- Internally Developed
Clinical Candidates 6 - Marketed Products
in China 3 - Global Team 2400+
BeiGene News
- June 19, 2019BeiGene Announces Updated Results from Two Ongoing Clinical Trials of Zanubrutinib in Patients with Mantle Cell Lymphoma in Presentations at the 15th International Conference on Malignant Lymphoma (ICML)
BeiGene Announces Updated Results from Two Ongoing Clinical Trials of Zanubrutinib in Patients with Mantle Cell Lymphoma in Presentations at the 15th International Conference on Malignant Lymphoma (ICML)
- June 18, 2019BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor
- June 17, 2019BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab
BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab
- June 14, 2019BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)
BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)
- June 14, 2019BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)
BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)
- June 12, 2019BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)
2010
- BeiGene was founded as a research and development company
2012
- Began work on an anti-PD-1 antibody and a BTK inhibitor
2014
- Started clinical trials of pamiparib and zanubrutinib
2016
- Went public on the Nasdaq, with $182 million initial public offering
2018
- 50+ ongoing or planned clinical trials
Partnering
Partnerships that ExtendAround the Globe
BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships
